Developer of transmembrane therapeutic peptides designed to identify peptidomimetic candidates suffering from hetero. The company's platform offers transmembrane therapeutic peptides having key competitive advantages over antibodies such as a improved drug discovery process and reduced manufacturing cost, enabling patients to buy medicines at comparatively low cost.
Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
---|---|---|---|---|---|---|
1. Seed Round | 15-Mar-2017 | $1.45M | 00.000 | 00.000 | Completed | Generating Revenue |
Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
---|---|---|---|---|---|---|---|---|
Ordinary | 0,000 | 00.000000 | 000.0 | 000.0 | 000.0 | 0.000 | ||
A | 0,000 | 00.000000 | 000.00 | 000.00 | 00 | 000.00 | 00.000 | |
Ordinary | 17,000 | $1.059897 |
Name | Title | Board Seat | Contact Info |
---|---|---|---|
Marjorie Sidhoum Ph.D | President | ||
Gerard Cremel | Co-Founder & Founding Member | ||
Dominique Bagnard Ph.D | Co-Founder | ||
Pascal Neuville | Co-Founder | ||
Pierre Hubert | Co-Founder |
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
---|---|---|---|---|---|
Capital Grand Est | PE/Buyout | Minority | 000 0000 | 000000 0 | |
Domain Therapeutics | VC-Backed Company | Minority | 000 0000 | 000000 0 |
Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
---|---|---|---|---|---|
0000 000000000000 | 08-Jun-2020 | 00000 00000 00 | Drug Discovery | 00000000 0000000 00.0 |